Viatris Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VTRS | TEVA | UTHR | MEGA.BK | 3933.HK | HYPE3.SA | |
|---|---|---|---|---|---|---|
| Market cap | 22.08B | 48.81B | 26.10B | 30.95B | 15.37B | 15.26B |
| P/E (TTM) | — | 97.3 | 23.0 | 14.2 | 28.9 | 8.1 |
| Forward P/E | 7.1 | 13.4 | 18.0 | 12.4 | 11.3 | 7.1 |
| Price/book | 1.6 | 6.1 | 4.1 | 3.0 | 0.8 | 1.0 |
| Dividend yield | 2.49% | — | — | 4.86% | 6.47% | 4.86% |
| 1-year change | +90.11% | +71.10% | +34.03% | +20.69% | −41.08% | −12.27% |
| Today | +1.59% | −0.14% | +1.19% | +1.43% | +6.41% | +2.90% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All VTRS news ›Viatris Q3 preview: What to expect
Viatris Q3 earnings preview: analysts see lower EPS, mixed estimate revisions, and risks from China, supply issues, and the Pacira deal. Healthcare firm Viatris’ (VTRS) third-quarter print is due on November 4, before the markets open,…
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Viatris VTRS, a global healthcare company, is expected to beat expectations when it reports third-quarter 2026 results on Nov. 5, before the opening bell. The Zacks Consensus Estimate for third-quarter revenues is pegged at $3.78 billion,…
Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?
How Far Did Viatris And Eli Lilly Raise Forecasts? The two raises are different news. Lilly’s adds to a business already growing fast, while Viatris’s is a small lift for a slow-growing business, made in spite of a hit to its supply.…
Xeris (NASDAQ: XERS) names ex-Viatris emerging markets president to its board
Posted by Michael Walen on Nov 2nd, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) appointed Menassie M. Taddese, a former Viatris emerging markets president, to its board on Nov. 2. He also joins the Audit Committee. The board grew…
Remifentanil Viatris
The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed ... NOTICE: This Consumer Medicine…
Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc
The Ashurst Perkins Coie team was led by Partner Jason Day, with a core team of Partners Jeff Beuche, Lisa McGimpsey, and Jon Schulman; Counsels Jackie Wilcox and Numaan Deen; and Associates Margaret Heitjan and Dani Buckles. To learn…
Viatris takes erectile dysfunction awareness campaign to Lagos streets
Global healthcare company Viatris has taken its EmpowerED for Life campaign to the streets of Lagos to promote open conversations about erectile dysfunction and encourage men to seek medical care without shame. The campaign, led by medical…
Viatris drives regional dialogue to advance cardiovascular care across Southeast Asia
Advancing a More Personalized Approach for Better Patient Outcomes Across the discussions, experts emphasized that effective cardiovascular care cannot take a one-size-fits-all approach. Understanding each patient’s risk profile and needs…
Viatris’ Dividend Has Room to Grow, but Will Management Deliver?
Viatris reported 5% revenue growth and raised its 2026 earnings guidance, while its 19% dividend payout ratio leaves room for income stability, but its GAAP losses raise questions about the quality of its recovery. Find VTRS among 10 Best…
Stryker, Viatris, Flo, Teva, J&J: This Week in Healthcare
After 14 years at Stryker's helm, during which time company revenue tripled, Kevin Lobo is stepping down as CEO and will begin his transition to the Executive Chair position. Spencer Stiles, who has spent nearly three decades at the US…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com8
- seekingalpha.com6
- stocktitan.net6
- investors.com3
- tradingview.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 66 articles, not a forecast.